ARIUS announces allowance of US patent for business lead anti-cancer antibody ARIUS Research Inc.

Such insights can be used to develop medicines, such as ARH460-16-2, to prevent the spread of tumor and prolong survival in tumor patients. Recently ARIUS in addition has announced the initiation of a toxicology program in preparation for individual clinical trials. ‘ARIUS can be having an extremely successful season,’ said Dr. David Little, CEO and President. ‘We have hit a number of critical specialized milestones and the ongoing achievement of our patent strategy reflects the value we are building in the company. We are moving ahead to file our IND application and begin human medical trials in 2008 with the U.S.Lotfi Benboubker, M.D., Meletios A. Dimopoulos, M.D., Angela Dispenzieri, M.D., John Catalano, M.D., Andrew R. Belch, M.D., Michele Cavo, M.D., Antonello Pinto, M.D., Katja Weisel, M.D., Heinz Ludwig, M.D., Nizar Bahlis, M.D., Anne Banos, M.D., Mourad Tiab, M.D., Michel Delforge, M.D., Jamie Cavenagh, M.D., Catarina Geraldes, M.D., Je-Jung Lee, M.D., Christine Chen, M.D., Albert Oriol, M.D., Javier de la Rubia, M.D., Lugui Qiu, M.D., Darrell J. White, M.D., Daniel Binder, M.D., Kenneth Anderson, M.D., Jean-Paul Fermand, M.D., Philippe Moreau, M.D., Michel Attal, M.D., Robert Knight, M.D., Guang Chen, Ph.D., Jason Van Oostendorp, M.Sc., Christian Jacques, M.D., Annette Ervin-Haynes, D.O.D., Cyrille Hulin, M.D., and Thierry Facon, M.D. For the Initial Trial Team: Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma For individuals with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation, the typical therapy is melphalan and prednisone coupled with either thalidomide or bortezomib .1-10 Lenalidomide is an immunomodulatory drug that, in combination with dexamethasone, is a standard treatment option for individuals with multiple myeloma who’ve received at least one prior therapy as approved by the Food and Drug Administration and the European Medicines Company.7-13 In a randomized trial that included both younger and older patients with newly diagnosed multiple myeloma, lenalidomide plus low-dosage dexamethasone was associated with fewer adverse occasions and a higher rate of general survival at 12 months than lenalidomide plus high-dosage dexamethasone , rendering it an option for individuals who are ineligible for stem-cell transplantation.